AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 22 min read$NBIX

Delaet Ingrid sold $354K of NBIX

Delaet Ingrid (Chief Regulatory Officer) sold 2,261 shares of NEUROCRINE BIOSCIENCES INC (NBIX) at $156.71 ($0.35M total) on 2026-05-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Delaet Ingrid
Published Jun 2, 2026, 10:03 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 2, 2026, 10:06 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$NBIX
Neutral
medium confidence
Mentioned
$NBIX
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NBIXNeutralLow
01

Why it matters

This adds a datapoint on insider behavior but does not introduce new company-specific fundamentals (no trial, approval, guidance, or legal/regulatory event mentioned).

02

Market read

Traders may note the insider sale for sentiment, but 10b5-1 typically limits tradable informational edge.

03

What to watch

Insider sale size vs. total holdings is not provided beyond post-transaction shares; without context on prior sales cadence, the signal is weak.

Relevance 6/10Novelty 3/10Timing: Filed June 2; sale executed May 29 (10b5-1 plan).

Background

SEC Form 4 disclosure of an officer’s transaction in the issuer’s common stock.

Company-level read

Ticker impact

$NBIXNeutralMedium confidence
Context

Neurocrine Biosciences insider (Chief Regulatory Officer) sold $354.3K of NBIX shares via an open-market sale under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and small unless paired with other catalysts.

Evidence & confidence

Form 4 provides a transaction datapoint without new operational/clinical/regulatory information; 10b5-1 indicates planned execution rather than new negative information.

Market effects

Sector

Minimal; this is company-specific insider activity with no stated sector-wide catalyst.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is 10b5-1, it may reflect routine liquidity planning rather than a view on fundamentals.

Key entities

  • issuer
    Neurocrine Biosciences, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Delaet Ingrid

    Chief Regulatory Officer who sold NBIX shares under a Rule 10b5-1 plan.

Read at source← All news

Related articles

AUG 1
$NBIXMed

Neurocrine Biosciences, Inc. Q2 2026 Earnings Call Summary

Neurocrine Biosciences reported Q2 2026 results and discussed its shift to a diversified portfolio. Management said INGREZZA record new patient additions supported raised full-year guidance midpoint for 13% YoY growth. CRENESSITY launch progress and Soleno and VYKAT XR acquisitions were highlighted. Soleno was $2.9B cash-funded; quarter-end cash was $500M and no debt.

yahoo.com7 min
JUL 31
$NBIXMedAI 8/10

Neurocrine (NBIX) Q2 2026 Earnings Call Transcript

Thursday, July 30, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Vice President of Investor Relations - Todd Tushla Chief Executive Officer - Kyle W. Gano Chief Financial Officer - Matthew Abernethy Chief Commercial Officer - Eric S. Benevich Chief Medical Officer - Sanjay Keswani Chief Business Officer - Samir Siddhanti Need a quote from a Motley Fool analyst?

fool.com7 min
JUL 30
$NBIXHigh

NEUROCRINE BIOSCIENCES INC (NBIX): Results of Operations and Financial Condition

NEUROCRINE BIOSCIENCES INC (NBIX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q2-2026xearningsrelease.htm EX-99.1 Document Exhibit 99.1 Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results Total Second-Quarter 2026 Revenue Grew 39% Year-Over-Year to $959 Million INGREZZA ® (valbenazine) 2026 Net Sales Guidance Raised to $2.825 to

SEC EDGAR 8-K6 min
JUL 9
$CRNXHighAI 9/10

Why Crinetics Stock Soared 99% This Week

Vertex (VRTX) agreed to acquire Crinetics (CRNX) for about $10B, or $85.00 per share in all cash, approved by both boards and expected to close in Q3 2026. CRNX shares rose about 99% to ~$83.54. Vertex projects the endocrine franchise could exceed $5B peak annual sales. Peers NBIX and CORT also gained on M&A expectations.

yahoo.com7 min
JUL 1
$NBIXMed

Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia

Neurocrine Biosciences (Nasdaq: NBIX) began a Phase 2 open-label, single-arm study of crinecerfont (CRENESSITY) in 20 children aged 3 months to under 4 years with classic congenital adrenal hyperplasia. The 24-week trial targets safety/tolerability and will assess PK/PD biomarkers, aiming to support a supplemental NDA to expand the U.S. indication. Enrollment also reached target in a EU Phase 2 study for birth to under 2 years.

prnewswire.com4 min